N-Fmoc-L-Pro Wang resin

• 分子结构分类: 有机化合物 - 苯类化合物 - 酚类
• 英文名称: N-Fmoc-L-Pro Wang resin
• 英文别名: Fmoc-Pro-Wang resin；N(2-hydroxy 4-nitrophenyl) N'-(2-phenylaminophenyl)urea；1-(2-anilinophenyl)-3-(2-hydroxy-4-nitrophenyl)urea
• 化学式: C₂₀H₁₈NO₃Pol
• 分子量: 364.4
• InChiKey: UHOSHUNGLMWKCU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  27
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  119
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-Fmoc-L-Pro Wang resin 在 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 Fmoc-Ala-Wang resin
  参考文献：
  名称：

  Structure–activity relationship study on polyglutamine binding peptide QBP1

  摘要：

  Aggregation and deposition of expanded polyglutamine proteins in the brain cause neurodegenerative diseases including Huntington disease. This pathogenic process is suppressed and delayed in the presence of polyglutamine binding peptide 1 (QBP1), which we previously identified as an undecapeptide binding to pathogenic polyglutamine proteins from phage display peptide libraries. In this paper, a structure activity relationship study on QBP1 was conducted to determine the pharmacophores for inhibition of polyglutamine aggregation. Furthermore, a truncation study identified an octapeptide as the minimum structure for suppressing aggregation of polyglutamine proteins, which is equipotent to the parent undecapeptide QBP1. (c) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2008.12.018
• 作为产物：
  描述：

  2-tertbutyldimethylsilyloxy 4-nitro phenyl isocyanate 、 邻氨基二苯胺 以 四氢呋喃 为溶剂， 生成 N-Fmoc-L-Pro Wang resin
  参考文献：
  名称：

  IL-8 receptor antagonists

  摘要：

  本发明涉及新化合物以及苯基脲在治疗由趋化因子白细胞介素-8（IL-8）介导的疾病状态中的新用途。

  公开号：

  US06262113B1

文献信息

• Synthesis and evaluation of conformationally constrained peptide analogues as the Src SH3 domain binding ligands
  作者：Rakesh Tiwari、Alex Brown、Seetha Narramaneni、Gongqin Sun、Keykavous Parang

  DOI：10.1016/j.biochi.2010.01.017

  日期：2010.9

  activity is a subject of major interest. Conformationally constrained peptides have been previously used for improving the binding potency of the Src SH2 domain binding peptide ligands and peptide substrates of the substrate-binding site of Src. A series of peptide analogues of Ac-VSLARRPLPPLP (1, Ac-VSL12, Kd=0.34 microM) were synthesized by introducing conformational constraints to improve the binding

  Src激酶活性受SH3域与富含脯氨酸残基的蛋白质序列相互作用的调节。可以调节Src激酶活性的更有效的SH3结构域结合配体的鉴定是一个重要的课题。构象受限的肽先前已用于改善Src SH2结构域结合肽配体和Src的底物结合位点的肽底物的结合能力。通过引入构象限制以改善对Src SH3结构域的结合亲和力，合成了一系列Ac-VSLARRPLPPLP的肽类似物（1，Ac-VSL12，Kd = 0.34 microM）。通过N末端至C末端[VSLARRPLPPLP]或N末端至侧链侧翼残基之间的环化合成的肽（即[βAVS] LARRPLPPLP和[VSLE] RRPLPPLP）显示至少6。与1相比，结合亲和力低4倍（Kd = 2.19-4.85 microM）。数据表明，在带有C末端或侧翼残基的N末端环化后，核心RPLPPLP中氨基酸的相互作用随残基显着降低在Src SH3域中。构象受限的肽V [SLA
• [EN] IL-8 RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RECEPTEURS D'IL-8
  申请人：SMITHKLINE BEECHAM CORPORATION

  公开号：WO1996025157A1

  公开（公告）日：1996-08-22

  (EN) This invention relates to the novel use of phenyl ureas in the treatment of disease states mediated by the chemokine, Interleukin-8 (IL-8).(FR) Cette invention se rapporte à une nouvelle utilisation des urées phényliques dans le traitement d'états pathologiques dont le médiateur est la chimiokine, appelée interleukine-8 (IL-8).

  该发明涉及苯基脲在治疗由趋化因子Interleukin-8 (IL-8)介导的疾病状态中的新用途。(中文翻译)
• The coordination abilities of the multiHis-cyclopeptide with two metal-binding centers – potentiometric and spectroscopic investigation
  作者：Aleksandra Kotynia、Sylwia Bielińska、Wojciech Kamysz、Justyna Brasuń

  DOI：10.1039/c2dt31224g

  日期：——

  centres able to undertake metal ion binding. The potentiometric and spectroscopic (UV-vis, CD and EPR) studies were carried out in aqueous solutions in the pH range 2.5–11.0 at 298 K, HNO3 was used as the solvent with KNO3, where the ionic strength was 0.1 M. The analysis of the potentiometric together with spectroscopic studies have shown that the investigated peptide forms only mono-nuclear complexes when

  在本文中，我们介绍了由八肽（c（HKHPHKHP））与铜（II）离子形成的单核和双核配合物。配体通过固相方法手动合成。其特有的循环结构显着影响协调能力。所研究的肽在序列中具有两个Pro氨基酸残基。这导致形成能够进行金属离子结合的两个独立的中心。电位和光谱（UV-vis，CD和EPR）研究是在298 K的pH范围为2.5–11.0的水溶液中进行的，HNO 3用KNO 3作为溶剂，离子强度为0.1M。电势分析和光谱研究表明，当金属与配体的摩尔比为1时，所研究的肽仅形成单核络合物： 1.当Cu（II）离子的浓度增加并且配体与金属的摩尔比为1∶2时，双核络合物的形成在该系统中是优选的。
• Structure–activity relationship study on polyglutamine binding peptide QBP1
  作者：Kenji Tomita、H. Akiko Popiel、Yoshitaka Nagai、Tatsushi Toda、Yuji Yoshimitsu、Hiroaki Ohno、Shinya Oishi、Nobutaka Fujii

  DOI：10.1016/j.bmc.2008.12.018

  日期：2009.2

  Aggregation and deposition of expanded polyglutamine proteins in the brain cause neurodegenerative diseases including Huntington disease. This pathogenic process is suppressed and delayed in the presence of polyglutamine binding peptide 1 (QBP1), which we previously identified as an undecapeptide binding to pathogenic polyglutamine proteins from phage display peptide libraries. In this paper, a structure activity relationship study on QBP1 was conducted to determine the pharmacophores for inhibition of polyglutamine aggregation. Furthermore, a truncation study identified an octapeptide as the minimum structure for suppressing aggregation of polyglutamine proteins, which is equipotent to the parent undecapeptide QBP1. (c) 2008 Elsevier Ltd. All rights reserved.
• Long-acting peptidomimetics based DPP-IV inhibitors
  作者：Pradip Jadav、Rajesh Bahekar、Shailesh R. Shah、Dipam Patel、Amit Joharapurkar、Samadhan Kshirsagar、Mukul Jain、Mubeen Shaikh、Kalapatapu V.V.M. Sairam

  DOI：10.1016/j.bmcl.2012.03.078

  日期：2012.5

  Pyrrolidine based peptidomimetics are reported as potent and selective DPP-IV inhibitors for the treatment of T2DM. Compounds 16c and 16d showed excellent in vitro potency and selectivity towards DPP-IV and the lead compound 16c showed sustained antihyperglycemic effects, along with improved pharmacokinetic profile. (C) 2012 Elsevier Ltd. All rights reserved.